1

2016 First-half resultsConference presentation for investors, analysts & media

Basel, 23 August 2016

2

This presentation contains certain forward-looking statements that reflect the current views ofmanagement. Such statements are subject to known and unknown risks, uncertainties andother factors that may cause actual results, performance or achievements of the StraumannGroup to differ materially from those expressed or implied in this presentation. Straumann isproviding the information in this presentation as of this date and does not undertake anyobligation to update any statements contained in it as a result of new information, futureevents or otherwise.

The availability and indications/claims of the products illustrated and mentioned in thispresentation may vary according to country.

Disclaimer

2

First-half highlightsMarco Gadola, CEO

Record H1 driven by strong all-round performance

4

R E V E N U E H 1 R E G I O N S & B U S I N E S S E S E B I T M A R G I N

+14% (organic1)

Double-digit growth 24.8%

H1: +14% (organic) and 16% (CHF)Q2: +15% (organic) and 16% (CHF)

Q2: first quarter in 8 years where all segments and regions post double-digit organic growth

Up 80 base points driven by strong volume growth and currency tailwind

K E Y P R O D U C T D R I V E R S T R A T E G I C H I G H L I G H T S G U I D A N C E 2 2 0 1 6

BLT >400k sold since launch

Expansionin high-growth segments/markets

Raisedexpectation for revenue growth

Every five implant Straumann sells is a BLT; more units sold in H1 than in entire 2015

Value segment entry in China; market entry in India

Low-double-digit organic revenue growth with further EBIT margin improvement

1 Organic growth – i.e. excluding the effects of currency fluctuations and acquired/divested business activities2 Barring unforeseen circumstances

3

5

North America28% of Group

Organic revenue growth in %

16.9

14.7

Q2 H1LATAM

9% of Group

EMEA 47% of Group

APAC16% of Group

14.713.5

Q2 H1

Group

11.110.2

Q2 H1

20.2 20.6

Q2 H1

17.2

15.6

Q2 H1

Positive sales trend continues in Q2

6

Revenue (CHF m) Gross margin2 (%) EBIT margin2 (%) EPS3 (CHF)

406.4

461.2

2015 2016

79.378.3

2015 2016

+13.5%1

24.5 24.8

2015 2016

4.59

5.99

2015 2016

+30bps+80bps excl. FX

+30%

1 Organic growth2 Excluding exceptionals and currency fluctuations 3 On an underlying basis, i.e. excluding one-time profit of CHF 41m in H1 2016 related to the capitalization of deferred tax assets in Brazil and business combination exceptionals in H1 2015

(100bps)(80bps) excl. FX

Operational gearing leads to further EBIT margin expansion

4

7

in C

HF

m

(1.0%) 1.2%

6.4%

9.1%

13.5%

2012 2013 2014 2015 H1 2016

Organic revenue growth

14.9%18.2%

20.9%

23.3% 24.8%

0%

10%

20%

30%

0

50

100

150

200

2012 2013 2014 2015 H1 2016

Operating profit

Operating income ExceptionalsUnderlying EBIT margin

in CHF million 2012 2013 2014 2015 H1 2016 5‐year average

Revenue 686.4 679.9 710.3 798.6 461.2

growth in %

Organic revenue growth ‐1.0 1.2 6.4 9.1 13.5 5.8

Acquisiton / Divesture ‐0.6 ‐0.8 0.0 9.5 1.4 1.9

Total l.c. growth ‐1.6 0.4 6.4 18.6 15.1 7.8

FX effect 0.5 ‐1.3 ‐1.9 ‐6.1 0.6 ‐1.7

Total revenue growth (in CHF) ‐1.1 ‐0.9 4.5 12.4 15.7 6.1

Accelerated growth dynamics

Business and regional reviewPeter Hackel, CFO

5

9

Overview of the underlying financial performance

Exceptionals: In H1 2016, net profit was lifted by a one-time effect of CHF 41m (or CHF 2.57 per share) related to the capitalization of deferred tax assets in Brazil. In H1 2015, exceptional charges related to the Neodent business combination reduced profit before income tax by CHF 77m and net profit by CHF 73m.

in CHF millionChange (rounded)

Reported Exceptionals excl. exceptionals Reported excl.

exceptionals

excl. exceptionals

and FX

excluding FX and exceptionals

Revenue 461.2 398.5 398.5 400.7Organic growth in % 13.5% 9.2%

Gross profit 361.2 301.9 315.0 317.6 14%

margin 78.3% 75.8% 79.1% 79.3% ( 100 bps) Distribution costs (102.4) (89.7) (90.0)

% of sales (22.2%) (22.5%) (22.5%)

Admininstrative expenses (145.6) (130.4) (130.5)

% of sales (31.6%) (32.7%) (32.6%)

EBITDA 129.2 98.6 111.7 113.5 14%% of sales 28.0% 24.8% 28.0% 28.3% ( 30 bps)

EBIT 114.4 82.7 95.8 98.0 17%

margin 24.8% 20.7% 24.0% 24.5% 30 bps

Finance result (0.9) (6.9) (6.9)

(63.9) 0.0

(0.6) (6.6) (6.6)

Taxes 22.0 40.5 (18.4) (5.9) (9.7)

Net profit 134.9 94.5 (0.7) 72.6 30%

margin 29.3% 20.5% (0.2%) 18.2% 230 bps

Basic EPS 8.55 5.99 (0.10) 4.59

Free cash flow 55.0 44.9 22%

margin 11.9% 11.3%

Loss on consilidation of Neodent

H1 2015H1 2016

Share of result of associates

75.8%

3.3% 0.2%

79.3%

1.9% (0.6%)(2.3%)

78.3%

Gross profitmargin H1

Businesscombinationexceptional

FX effect Adj. gross profitmargin H1

Higher volume /price

Inventory change/ plant utilization

Material, labor &mix

Gross profitmargin H1

In % of revenue, rounded

Gross margin constrained by production investments and higher share of value products

10

1 Business combination exceptionals: inventory revaluation expenses of CHF 13m in H1 2 Change in finished and semi-finished goods in 2016 compared with same period a year earlier3 Higher material usage, increased production staff, as well as higher share of value & 3rd party products

1

2016

(100 bps) excl. FX

2 3

(80 bps)

2015

6

20.7%

3.3%0.5%

24.5%

(1.0%)0.3%

1.0%

24.8%

Reported EBITmargin H1

Businesscombinationexceptional

FX effect Adjusted EBITmargin H1

Change in grossmargin

Expansion ofdistribution

R&D, Marketing& administration

EBIT margin H1

EBIT margin improves despite further investments in distribution and innovation

11

20162015

In % of revenue, rounded

+30 bpsexcl. FX

1

+80 bps

(0.7)

73.2

72.6

18.66.1

6.0 (8.8)

94.5

40.5

134.9

Reported H1net profit

Businesscombinationexceptional

Adjusted H1net profit

EBITimprovement

Financialresult

Associateresult

Income taxes Adjusted netprofit H1

One-time taxgain

Reported H1net profit

12

Underlying net profit margin clears 20%

In CHF million, rounded

Net profit margin 20.5%

1 Share of results from associates in 2015 included the contribution from Neodent, which was reduced by provisions related to a local distributor agreement and ongoing litigation.

2 One-time effect of CHF 41 million (corresponding to CHF 2.57 earnings per share) related to the capitalization of deferred tax assets in Brazil..

2

Net profit margin 18.2%

20162015

1

7

44.9

30.53.6 (37.2)

10.9 2.4

55.0

Free cash flowH1 2015

EBITDAimprovement

Change in CAPEX Change in NWC Difference in non-cash OPEX

Change in interest,taxes and others

Free cash flowH1 2016

Solid cashflow generation

FCF margin 11.9%

FCF margin 11.3%

13

Chart shows cash-relevant changes January-June 2016 compared with the same period in 20151 Mainly changes in share-based payments and provisions

1

Days of supplies (DOS): 148 (2015: 156)

Days of sales outstanding (DSO): 61 (2015: 64)

In CHF million, rounded

Change in organic growth

14

Double-digit growth across all regions

13.5% organic

Revenue development (in CHF million, rounded)

2015 2016

0.6% 14.7% 15.6%10.2% 20.6%1.4%

15.7% in CHF

Contribution to growth

EMEA

NorthAmerica

APAC

LATAM

37%

29%

23%

11%

398.5

2.2 5.7

406.4

20.0

16.1

12.85.9

461.2

RevenuesH1 2015

FX effect M&A effect RevenuesH1 2015 @

FX 2016

EMEA NorthAmerica

APAC LATAM RevenuesH1 2016

8

Revenue change (organic)

56%

Momentum improves as revenue climbs 11% in Q2

Italy, Spain, France, & Sweden grow fastest. Germany & Switzerland report expected acceleration.

Good start in Russia; healthy demand in distributor markets

11.1% 9.4% 8.3% 8.5% 8.3%

0.3%

Q2Q12016

Q4Q3Q2Q12015

EM

EA

No

rth

Am

eric

a BLT helps win new customers; PURE® ceramic implant launched

Q2 (+17%) lifted by BLT and Pro Arch; prosthetic business accelerates

Instradent launches Medentika cost-effective prosthetic solutions

28%

15

EMEA into double-digit growth; New leadership adds dynamism in N. America

16.9%

12.5%

6.6% 6.1%

9.3% 11.6%

Q2Q12016

Q4Q3Q2Q12015

47%

56%

Q2: strong performance by all subsidiaries

Dynamic growth in China; entry into value segment with Anthogyrbrand

Further share gains in Japan; large symposium with high proportion of new customers

20.2%21.0%20.0%

13.2%12.8%

34.5%

Q2Q12016

Q4Q3Q2Q12015

Asi

aP

acif

icL

ATA

M

17.2%

13.3%16.8%

1.3%

15.6%

8.3%

Q2Q12016

Q4Q3Q2Q12015

Q2 acceleration despite economic challenges in several markets

Premium and value brands grow impressively in Brazil and Mexico, fuelled by new products/solutions

Production expansion in Curitiba to meet growing demand for Neodent

16%

9%

16

APAC & LATAM keep the pace up

Revenue change (organic)

Owing to the Neodent acquisition, the respective regional growth figures in LATAM for 2015 have been recalculated on a pro-forma basis and include the Straumann as well as the Neodent business to allow for a true comparison.

9

Implants

Double-digit growth in all businesses

17

Restorative Biomaterials

Update on our strategic progressMarco Gadola, CEO

10

19

Update on our strategic priorities

Drive a high performance culture and organization

Target unexploited growth markets & segments

Become a total solution provider for tooth replacement

1

2

3

20

Update on our strategic priorities

Drive a high performance culture and organization

Target unexploited growth markets & segments

Become a total solution provider for tooth replacement

1

2

3

11

21

Strong performance – evidence of cultural change @ Straumann

Strategy Culture

VisionMore than creating smiles,

restoring confidence –we want to be the partner of choice for tooth

replacement solutions.

What wewant toachieve

How we will achieve it

22

Update on our strategic priorities

Drive a high performance culture and organization

Target unexploited growth markets & segments

Become a total solution provider for tooth replacement

1

2

3

12

23

Straumann exercises rights/options to obtain controlling stake in MegaGen

Bonds totaling USD 30m converted

Option exercised to purchase additional shares

to obtain a controlling stake

Conversion rate and purchase price to be

determined by ICC arbitration (could take up to

2 years)

24

Straumann enters Chinese value segmentwith Anthogyr

30% stake in Anthogyr acquired in March

Anthogyr’s implantology business activities in China

transferred to Straumann at end of June

Straumann gains immediate presence in fast-growing

value segment in China

>5000 Anthogyr implants sold since transfer

13

25

Straumann invests in underpenetrated, fast-growing Indian market

Agreement to acquire Equinox, a leader in

India’s value segment (14% overall market

share) with a growing international business

Huge need for tooth-replacement; India is

one of the least penetrated markets (~220k

implants placed in 2015: 2 per 10k

population1)

Equinox’ networks, experience &

organization to help establish Straumann in

multi-brand approach

Founding CEO to head Straumann India

Logistics supplier network

1 Straumann estimates

26

at a glance

Develops, manufactures & sells own cost-effective

implant system based on proven concepts with

innovative enhancements

2015 revenue of approx. 200m rupees (~CHF 3m)

with solid operating profit

Ranks among top 3 implant companies in India

Offices & production in Mumbai; 75 employees

Distributors in Asia, Africa and Middle East

14

Premium ValueCommon technology andmanufacturing platform

Value platform expanded

Brazil (100%) Germany (51%)

S. Korea(arbitration)

Spain (30%)

Canada (55%)

Germany

Germany (100%)

27

Taiwan (49%)

USA (13%)

Switzerland (44%)

Austria

Taiwan(conv. bond)

France (30%)

India (100%)(coming months)

Implants CADCAM/prosthetics Regeneratives

Turkey (50%)(Joint venture)

28

Straumann takes over exclusive distribution of botiss biomaterials in important German market from Q3

botiss’ sales team in Germany transfers to Straumann

botiss to focus on development and innovation

Strong fruitful partnership between companies

Biomaterials – leadership ambition in Europe

15

29

Update on our strategic priorities

Drive a high performance culture and organization

Target unexploited growth markets & segments

Become a total solution provider for tooth replacement

1

2

3

Investing in people to create and drive growth opportunities

3471 3599

0

1000

2000

3000

4000

FY 2015 HY 2016

Group employees

Expansion in:

China (value segment)

Russia (new subsidiary)

France, LATAM (Sales)

UK (Sales; Instradent)

USA (Production; Instradent)

Switzerland (Sales;Logistics; R&D)

128 new colleagues

31 Dec 2015 30 Jun 2016

16

31

Changes in Board of Directors

After departure of Stefan Meister, Ulrich Looser took over as Chairman of

Compensation Committee (CC) and Thomas Straumann joined the CC

Regula Wallimann agrees to stand for election to the Board at AGM in

April 2017

• Expert in multinational group auditing and financial advisory

• KPMG since 1993

• Global Lead Partner since 2003 with responsibility for several global companies

• Certified Public Accountant in US and Switzerland

• New career as independent financial expert and professional board member

Outlook 2016

17

33

Guidance 2016 Barring unforeseen circumstances

Straumann expects the global implant

market to grow solidly in 2016 and is

confident that it can continue to outperform

Aims to achieve full-year organic growth in

the low-double-digit range

Despite further investments in strategic

growth initiatives, the expected revenue

growth and operational leverage should lead

to further improvements in the underlying

full-year EBIT margin (2015: 23%).

Questions & answers

18

Calendar of upcoming events

35

2016

23 August Half-year results conference HQ, Basel

23 August Analyst Talk 7th edition Straumann website

30 August Commerzbank Sector Conference Frankfurt, Germany

06 September Investor meetings London, UK

07 September Goldman Sachs HC conference London, UK

14 September BKB Investor Event Basel, Switzerland

16 September UBS Best of Switzerland Conference Ermatingen, Switzerland

27 October Q3 revenue publication Webcast

2017

16 February Full-year results conference HQ, Basel

07 April AGM 2016 Messe Basel

More information on straumann.com → Events

CHF37%

EUR19%

USD/CAD/AUD24%

BRL11%

Other11%

CHF9%

EUR33%

USD/CAD/AUD29%

BRL10%

Other19%

36

Straumann’s currency exposure

Cost breakdown FY20151

Revenue breakdown FY20151

1 These distribution charts represent the total net revenues and the total COGS, as well as OPEX in the various currencies. All numbers are rounded and based on FY 2015 figures and include Neodent since 1 March.

Average exchange rates (rounded)FX sensitivity

(+/- 10%) on full-year...

2014 2015 H1 2016 Revenue EBIT

1 EURCHF 1.21 1.08 1.10 +/- 26m +/- 16m

1 USDCHF 0.92 0.96 0.99 +/- 20m +/- 7m

1 BRLCHF 0.389 0.295 0.268 +/- 8m +/- 2m

100 JPYCHF 0.86 0.88 0.86 +/- 5m +/- 3m

36

50

70

90

110

130

2014 2015 2016

EURCHF BRLCHF USDCHF JPYCHF

19

37

Your contacts

Corporate Investor Relations

Fabian Hildbrand

Tel. +41 (0)61 965 13 27

investor.relations@straumann.com

Corporate Communications

Mark Hill Thomas Konrad

Tel. +41 (0)61 965 13 21 Tel. +41 (0)61 965 15 46

mark.hill@straumann.com thomas.konrad@straumann.com

International Headquarters

Institut Straumann AG

Peter Merian-Weg 12

CH-4002 Basel, Switzerland

Phone +41(0)61 965 11 11

Fax +41(0)61 965 10 01

www.straumann.com